Clinical Trials Logo

Leukemia, B-Cell clinical trials

View clinical trials related to Leukemia, B-Cell.

Filter by:

NCT ID: NCT04649983 Recruiting - Lymphoma, B-Cell Clinical Trials

CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma

Start date: September 1, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This is a single arm study to evaluate the efficacy and safety of CD19 and CD22 targeted CAR-T cells therapy for patients with relapsed/refractory B Cell Leukemia and Lymphoma.

NCT ID: NCT04648475 Recruiting - Lymphoma, B-Cell Clinical Trials

Safety and Efficacy of CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma

Start date: August 25, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This is a single arm study to evaluate the efficacy and safety of CD19 and CD22 targeted CAR-T cells therapy for patients with relapsed/refractory B Cell Leukemia and Lymphoma.

NCT ID: NCT04516551 Recruiting - B Cell Leukemia Clinical Trials

Anti-CD19 Allo-CAR-T Cells for Relapsed B Cell Malignancies After HSCT

Start date: November 20, 2020
Phase: Phase 1
Study type: Interventional

The patients with relapsed B cell acute lymphoblastic leukemia (ALL) after hematopoietic stem cell transplant (HSCT) have a poor prognosis, especially for these relapsed in a short time after transplantation. Nowadays there is no effective way to salvage patients in such conditions. T cells derived from healthy matched sibling or unrelated donors have not been restrained by tumor micro-environment and retain anti-leukemia ability, which makes it serve well for patients with relapsed B-ALL. So we launched a multi-center clinical trial to proved the safety and efficacy of anti-CD19 CAR-T cells for relapsed B cell ALL.

NCT ID: NCT04439721 Recruiting - Leukemia, B-cell Clinical Trials

γδT Cell Infusion to Prevent Relapsed/Refractory Leukemia Rescue Relapse

?dT
Start date: May 1, 2020
Phase: Early Phase 1
Study type: Interventional

Safety and Effectiveness of Donor γδT Cell Infusion to Prevent Relapsed/Refractory Leukemia Rescue Relapse After Allogeneic Hematopoietic Stem Cell Transplantation

NCT ID: NCT04271800 Recruiting - Lymphoma Clinical Trials

Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma

Start date: December 1, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This is a single arm study to evaluate the efficacy and safety of CD19-targeted CAR-T cells therapy for patients with relapsed/refractory CD19+ B Cell Leukemia and Lymphoma.

NCT ID: NCT04271410 Recruiting - Leukemia Clinical Trials

CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma

Start date: June 1, 2019
Phase: Phase 1/Phase 2
Study type: Interventional

This is a single arm study to evaluate the efficacy and safety of CD19-targeted CAR-T cells therapy for patients with relapsed/refractory CD19+ B Cell Leukemia and Lymphoma.

NCT ID: NCT04260945 Completed - B-cell Leukemia Clinical Trials

CD19/CD20 Dual-CAR-T in B-cell Leukemia Patients

Start date: March 10, 2020
Phase: Phase 1
Study type: Interventional

This is a single center, single arm, open-label, phase I study to evaluate the safety and efficacy of CD19/CD20 Dual-CAR-T cells in patients with refractory and relapsed B-cell leukemia.

NCT ID: NCT04156243 Recruiting - B Cell Lymphoma Clinical Trials

CD19 CARvac T Cells for Patients With Relapsed / Refractory B Cell Malignancies

Start date: February 1, 2018
Phase: Early Phase 1
Study type: Interventional

This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of CD19 CARvac in patients with relapsed and/or refractory B cell malignancies.

NCT ID: NCT04156178 Recruiting - B Cell Lymphoma Clinical Trials

CD20-CD19 Compound CAR (cCAR) T Cells for Patients With Relapsed /Refractory B Cell Malignancies

Start date: August 1, 2018
Phase: Early Phase 1
Study type: Interventional

This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of CD20-CD19 cCAR in patients with relapsed and/or refractory B cell malignancies.

NCT ID: NCT04100187 Not yet recruiting - Leukemia Clinical Trials

Immunotherapy With CD19 CAR T-cells for B-Cell Leukemia

Start date: February 1, 2023
Phase: Phase 1
Study type: Interventional

This study aims to evaluate the safety, efficacy and duration of response of CD19 Chimeric Antigen Receptor (CAR) redirected autologous T-cells in patients with high risk, relapsed CD19+ haematological malignancies.